Your browser doesn't support javascript.
loading
Patient views regarding cannabis use in chronic kidney disease and kidney failure: a survey study.
Collister, David; Herrington, Gwen; Delgado, Lucy; Whitlock, Reid; Tennankore, Karthik; Tangri, Navdeep; Goupil, Remi; Nadeau-Fredette, Annie-Claire; Davison, Sara N; Wald, Ron; Walsh, Michael.
Afiliación
  • Collister D; Division of Nephrology, Department of Medicine, University of Alberta, Edmonton, AB, Canada.
  • Herrington G; Department of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada.
  • Delgado L; Department of Anesthesia, McMaster University, Hamilton, ON, Canada.
  • Whitlock R; Population Health Research Institute, Hamilton, ON, Canada, Chronic Disease Innovation Centre, Winnipeg, MB, Canada.
  • Tennankore K; Can-SOLVE CKD, University of British Columbia, Vancouver, BC, Canada.
  • Tangri N; Can-SOLVE CKD, University of British Columbia, Vancouver, BC, Canada.
  • Goupil R; Chronic Disease Innovation Centre, Winnipeg, MB, Canada.
  • Nadeau-Fredette AC; Division of Nephrology, Department of Medicine, Dalhousie University, Nova Scotia Health Authority, Halifax, NS, Canada.
  • Davison SN; Department of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada.
  • Wald R; Chronic Disease Innovation Centre, Winnipeg, MB, Canada.
  • Walsh M; Division of Nephrology, Hôpital du Sacré-Cœur de Montréal, Montreal, QC, Canada.
Nephrol Dial Transplant ; 38(4): 922-931, 2023 03 31.
Article en En | MEDLINE | ID: mdl-35881478
ABSTRACT

BACKGROUND:

Cannabis is frequently used recreationally and medicinally, including for symptom management in patients with kidney disease.

METHODS:

We elicited the views of Canadian adults with kidney disease regarding their cannabis use. Participants were asked whether they would try cannabis for anxiety, depression, restless legs, itchiness, fatigue, chronic pain, decreased appetite, nausea/vomiting, sleep, cramps and other symptoms. The degree to which respondents considered cannabis for each symptom was assessed with a modified Likert scale ranging from 1 to 5 (1, definitely would not; 5, definitely would). Multilevel multivariable linear regression was used to identify respondent characteristics associated with considering cannabis for symptom control.

RESULTS:

Of 320 respondents, 290 (90.6%) were from in-person recruitment (27.3% response rate) and 30 (9.4%) responses were from online recruitment. A total of 160/320 respondents (50.2%) had previously used cannabis, including smoking [140 (87.5%)], oils [69 (43.1%)] and edibles [92 (57.5%)]. The most common reasons for previous cannabis use were recreation [84/160 (52.5%)], pain alleviation [63/160 (39.4%)] and sleep enhancement [56/160 (35.0%)]. Only 33.8% of previous cannabis users thought their physicians were aware of their cannabis use. More than 50% of respondents probably would or definitely would try cannabis for symptom control for all 10 symptoms. Characteristics independently associated with interest in trying cannabis for symptom control included symptom type (pain, sleep, restless legs), online respondent {ß = 0.7 [95% confidence interval (CI) 0.1-1.4]} and previous cannabis use [ß = 1.2 (95% CI 0.9-1.5)].

CONCLUSIONS:

Many patients with kidney disease use cannabis and there is interest in trying cannabis for symptom control.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Síndrome de las Piernas Inquietas / Cannabis / Insuficiencia Renal Crónica Tipo de estudio: Prognostic_studies Límite: Adult / Humans País/Región como asunto: America do norte Idioma: En Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Síndrome de las Piernas Inquietas / Cannabis / Insuficiencia Renal Crónica Tipo de estudio: Prognostic_studies Límite: Adult / Humans País/Región como asunto: America do norte Idioma: En Año: 2023 Tipo del documento: Article